Endoter

Company Overview

Snapshot

Founded in September 2025, Endoter operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of its core technology.

Business overview

Endoter (EndorTech) is an Israeli healthtech startup developing synthetic biological beta-endorphin formulations delivered via aerosol as a natural alternative to opioid painkillers. The company focuses on providing potent, targeted pain relief with fewer side effects and at competitive cost, aiming to replace conventional opioid-based therapies in multiple clinical settings. Its team combines neuroscience, biopharma, and medical-device experience to design protected delivery systems and advance next-generation pain management solutions from early development toward clinical and commercial readiness, operating within the Medical Devices and Medical Treatment & Therapeutics sectors.

Company Intelligence Q&A

What is Endoter's primary focus?

Endoter is developing synthetic beta-endorphin formulations delivered via aerosol to provide non-opioid pain relief, aiming to offer a natural alternative to conventional opioid-based therapies.

When was Endoter founded?

Endoter was founded in September 2025.

What problem is Endoter trying to solve?

Endoter is addressing the need for potent, targeted pain relief with fewer side effects and at a competitive cost, seeking to replace conventional opioid-based therapies.

What stage of development is Endoter currently in?

Endoter is currently in the Pre-Funding stage, with its product in the R&D phase.

What expertise does Endoter's team bring?

Endoter's team combines neuroscience, biopharma, and medical-device experience to design protected delivery systems and advance pain management solutions.